Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)

  • Chronic Leukemia
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Abstract

Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies. These agents have anti-inflammatory, antiangiogenic, and immunomodulatory properties, and target tumor cells by direct cytotoxicity and indirectly by interfering with several components of the bone marrow microenvironment [1]. Thalidomide analogs that retain antitumor activity equal to or greater than the parent compound, but with less toxicity, have been developed [2]. This paper summarizes what is known about the mechanisms of action of these agents, and recent clinical results. The data suggest that thalidomide analogs will play a major role in the management of certain hematologic neoplasms in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC: Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 49:1238–1245, 2008. doi:10.1080/10428190802005191

    Article  PubMed  CAS  Google Scholar 

  2. Aragon-Ching JB, Li H, Gardner ER, Figg WD: Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Discov 2:167–174, 2007.

    Article  CAS  Google Scholar 

  3. Paravar T, Lee DJ: Thalidomide: mechanisms of action. Int Rev Immunol 27:111–135, 2008. doi:10.1080/08830180801911339

    Article  PubMed  CAS  Google Scholar 

  4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571, 1999. doi:10.1056/NEJM199911183412102

    Article  PubMed  CAS  Google Scholar 

  5. Zhu D, Corral LG, Fleming YW, et al.: Immunomodulatory drugs Revlamid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.␣Cancer Immunol Immunother, 2008, 57:1849–1851

    Google Scholar 

  6. Lu L, Payvandi F, Wu L, et al.: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res, in press, 2008

  7. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB: Lenalidomide enhances natural killer cells and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650–4657, 2008. doi:10.1158/1078-0432.CCR-07-4405

    Article  PubMed  CAS  Google Scholar 

  8. Liu Q, Farley KL, Johnson KA, et al.: Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit, in press, 2008

  9. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, Laskin OL: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Clin Pharmacol 47:1466–1475, 2007. doi:10.1177/0091270007309563

    Article  CAS  Google Scholar 

  10. Blansfield JA, Caragacianu D, Alexander HR III, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK: Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270–280, 2008. doi:10.1158/1078-0432.CCR-07-1562

    Article  PubMed  CAS  Google Scholar 

  11. Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K: Pomalidomide and lenalidomide regulate eryhtropoiesis and fetal hemoglobin production in human CD34 + cells. J Clin Invest 118:248–258, 2008. doi:10.1172/JCI32322

    Article  PubMed  CAS  Google Scholar 

  12. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dörken B, Zenke M, Lentzsch S: Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing eryhtropoiesis and promoting myelopoiesis. Blood 105:3833–3840, 2005. doi:10.1182/blood-2004-03-0828

    Article  PubMed  CAS  Google Scholar 

  13. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465, 2006. doi:10.1056/NEJMoa061292

    Article  PubMed  CAS  Google Scholar 

  14. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA: Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87:345–352, 2008. doi:10.1007/s00277-008-0449-0

    Article  PubMed  CAS  Google Scholar 

  15. Kelaidi C, Eclache V, Fenaux P: The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol 140:267–278, 2008. doi:10.1111/j.1365-2141.2007.06910.x

    Article  PubMed  CAS  Google Scholar 

  16. Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Helström-Lindberg E: Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 104:11406–11411, 2007. doi:10.1073/pnas.0610477104

    Article  PubMed  CAS  Google Scholar 

  17. Ebert BL, Galili N. Tamayo P, Bosco J, Mak R, Pretz J, Tanguturi S, Ladd-Acosta C, Stone R, Golub TR, Raza A: An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5:e35, 2008. doi:10.1371/journal.pmed.0050035

    Article  PubMed  CAS  Google Scholar 

  18. Van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B: First thalidomide clinical trial in multiple myeloma: a decade. Blood 112:1035–1038, 2008. doi:10.1182/blood-2008-02-140954

    Article  PubMed  CAS  Google Scholar 

  19. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436, 2006. doi:10.1200/JCO.2005.03.0221

    Article  PubMed  CAS  Google Scholar 

  20. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Bladé J: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171–2177, 2008. doi:10.1200/JCO.2007.14.1853

    Article  PubMed  CAS  Google Scholar 

  21. Von Lillienfeld-Toal M, Hahn-Ast C, Furkert K, et al.: A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol, 2008, 81:247–252

  22. Barlogie B, Van Rhee F, Shaughnessy JD Jr, et al.: Seven year median time to progression with thalidomide for smouldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008, 112:3122–3125

    Google Scholar 

  23. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-loiseau H: Melphalan and prednisone plus thalidomide versus melphaln and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 370:1209–1218, 2007. doi:10.1016/S0140-6736(07)61537-2

    Article  PubMed  CAS  Google Scholar 

  24. Palumbo A, Bringhen S, Liberati AM, et al.: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood, 2008, 112:3107–3114

    Google Scholar 

  25. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhhal A, Romdhane NB, Omri HE, Elloumi M, Belaaj H, Jeddi R, Aissaouï L, Ksouri H, Hassen AB, Msadek F, Saad A, Hsaïri M, Boukef K, Amouri A, Louzir H, Dellagi K, Abdeladhim AB: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111:1805–1810, 2008. doi:10.1182/blood-2007-07-101212

    Article  PubMed  CAS  Google Scholar 

  26. Barlogie B, Pineda-Roman M, van Rhee F, et al.: Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 2008, 112:3115–3121

    Google Scholar 

  27. Chang JE, Juckett MB, Callander NS, Kahl BS, Gangnon RE, Mitchell TL, Longo WL: Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma 8:153–158, 2008. doi:10.3816/CLM.2008.n.018

    Article  PubMed  CAS  Google Scholar 

  28. Breitkreutz I, Anderson KC: Thalidomide in multiple myeloma-clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4:973–985

  29. Palumbo A, Facon T, Sonneveld P, Bladé J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL: Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968–3977, 2008. doi:10.1182/blood-2007-10-117457

    Article  PubMed  CAS  Google Scholar 

  30. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K: A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34:442–452, 2008. doi:10.1016/j.ctrv.2008.02.003

    Article  PubMed  CAS  Google Scholar 

  31. Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A: The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141:814–819, 2008. doi:10.1111/j.1365-2141.2008.07147.x

    Article  PubMed  CAS  Google Scholar 

  32. Terpos E, Kastritis E, Roussou M, et al.: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, in press, 2008

  33. Treon SP, Soumerai JD, Branagan AR, et al.: Thalidomide and rituximab in Waldenstrom’s macroglobulinemia. Blood, in press, 2008

  34. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, Lopez-Girona A, Muller GW, Brady HA, Chan KW: Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells. Cancer Res 67:746–755, 2007. doi:10.1158/0008-5472.CAN-06-2317

    Article  PubMed  CAS  Google Scholar 

  35. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107:3098-3105, 2006. doi:10.1182/blood-2005-08-3450

    Article  PubMed  CAS  Google Scholar 

  36. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA: Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 141: 41–51, 2008. doi:10.1111/j.1365-2141.2008.07013.x

    Article  PubMed  CAS  Google Scholar 

  37. Schey SA, Fields P, Bartlett JB, Clarke IA, Aahan G, Knight RD, Streetly M, Dalgleish AG: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22:3269–3276, 2004. doi:10.1200/JCO.2004.10.052

    Article  PubMed  CAS  Google Scholar 

  38. Breitkreutz I, Raab MS, Vallet S, et al.: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia, 2008, 22:1925–1932

    Google Scholar 

  39. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132, 2007. doi:10.1056/NEJMoa070594

    Article  PubMed  CAS  Google Scholar 

  40. Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesyckyj M, Zeldis JB, Knight RD: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142, 2007. doi:10.1056/NEJMoa070596

    Article  PubMed  CAS  Google Scholar 

  41. Wang M, Dimopoulos MA, Chen C, et al.: Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood, in press, 2008

  42. Rajkumar SV, Hayman SR, Lacy MO, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050–4053, 2005. doi:10.1182/blood-2005-07-2817

    Article  PubMed  CAS  Google Scholar 

  43. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M: BiRD (Biaxin [clarithromycin]/ Revlamid [lenalidomide]/ dexamethasone) combination therapy results in high complete-and overall –response rates in treatment-naïve symptomatic multiple myeloma. Blood 111:1101–1109, 2008 doi:10.1182/blood-2007-05-090258

    Article  PubMed  CAS  Google Scholar 

  44. Spahn JD, Fost DA, Covar R Martin RJ, Brown EE, Szefler SJ, Leung DY: Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87:501–505, 2001.

    Article  PubMed  CAS  Google Scholar 

  45. Ohara T, Monishita T, SuzukiH, Massaoka T, Ishi H, Hibi T: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 24:3723–3730, 2004.

    PubMed  CAS  Google Scholar 

  46. Paripati H, Stewart AK, Cabou S, et al.: Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282–1284. doi:10.1038/sj.leu.2405100

  47. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S: Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated myeloma patients. Leukemia 22:1280–1281, 2008. doi:10.1038/sj.leu.2405035

    Article  PubMed  CAS  Google Scholar 

  48. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R: Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 14:795–798, 2008. doi:10.1016/j.bbmt.2008.04.008

    Article  PubMed  CAS  Google Scholar 

  49. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A: Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 8:865–874, 2008. doi:10.1586/14737140.8.6.865

    Article  PubMed  CAS  Google Scholar 

  50. Armoiry X, Aulagner G, Facon T: Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 33:219–226, 2008. doi:10.1111/j.1365-2710.2008.00920.x

    Article  PubMed  CAS  Google Scholar 

  51. Dimopoulos MA, Kastritis E, Rajkumar SV: Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22:1343–1353, 2008. doi:10.1038/leu.2008.123

    Article  PubMed  CAS  Google Scholar 

  52. Hideshima T, Raje N, Richardson PG, Anderson KC: A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag 4:129–136, 2008.

    PubMed  CAS  Google Scholar 

  53. Caers J, Vande Broek I, De Raeve H, et al.: Multiple myeloma, an update on diagnosis and treatment. Eur J Haematol, 2008, 81:329–343

    Google Scholar 

  54. Anargyrou K, Dimopoulos MA, Sezer O, Terpos E: Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma 49:677–689, 2008. doi:10.1080/10428190701861686

    Article  PubMed  CAS  Google Scholar 

  55. Moreau P, Hulin C, Facon T: Frontline treatment of multiple myeloma in elderly patients. Blood Rev, 2008, 22:303–309

    Google Scholar 

  56. Palumbo A, Miguel JS, Sonneveld P, Moreau P, Drach J, Morgan G, Einsele H: Lenalidomide: a new therapy for multiple myeloma. Cancer Treat Rev 34:283–291, 2008. doi:10.1016/j.ctrv.2007.12.005

    Article  PubMed  CAS  Google Scholar 

  57. Palumbo A, Dimopoulos M, Miguel JS, et al.: Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev, in press, 2008

  58. Mateos MV, Garcia-Sanz R, Colado E, Olazábal J, San-Miguel J: Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 140:324–326, 2008. doi:10.1111/j.1365-2141.2007.06946.x

    Article  PubMed  CAS  Google Scholar 

  59. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM: Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 29:1–8, 2008.

    Google Scholar 

  60. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520, 2008. doi:10.1182/blood-2007-10-116129

    Article  PubMed  CAS  Google Scholar 

  61. Chanan-Khan A, Porter CW, Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol 7:480–488, 2006. doi:10.1016/S1470-2045(06)70723-9

    Article  PubMed  CAS  Google Scholar 

  62. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczmzn MS: Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106:3348–3352, 2005. doi:10.1182/blood-2005-02-0669

    Article  PubMed  CAS  Google Scholar 

  63. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24:5343–5349, 2006. doi:10.1200/JCO.2005.05.0401

    Article  PubMed  CAS  Google Scholar 

  64. Ferrajoli A, Lee BN, Schlette EJ, O’Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291–5297, 2008. doi:10.1182/blood-2007-12-130120

    Article  PubMed  CAS  Google Scholar 

  65. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519–2525, 2008. doi:10.1200/JCO.2007.13.9709

    Article  PubMed  CAS  Google Scholar 

  66. Moutouh-de-Parseval LA, Weiss L, DeLAp RJ, Knight RD, Zeldis JB: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25:5047, 2007. doi:10.1200/JCO.2007.14.2141

    Article  PubMed  Google Scholar 

  67. Chanan-Khan AA, Whitworth A, Bangia N, et al.: Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol, 2008, 26:4851–4852

    Google Scholar 

  68. Lapalombella R, Yu B, Triantafillou G, et al.: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, in press, 2008

  69. Srinivasan S, Schiffer CA: Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leuk Res, in press, 2008

  70. Makower D, Venkatraj U, Dutcher JP, Wiernik PH: Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leuk Lymphoma 23:617–619, 1996. doi:10.3109/10428199609054873

    Article  PubMed  CAS  Google Scholar 

  71. Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 140:313–319, 2008. doi:10.1111/j.1365-2141.2007.06937.x

    Article  PubMed  CAS  Google Scholar 

  72. Gottardi M, Danesin C, Canal F, Paolo Dei Tos A, Maria Stefani P, Calistri E, Salvadori U, Gherlinzoni F: Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation. Leuk Lymphoma 25:1–3, 2008.

    Google Scholar 

  73. Xu W, Celeridad M, Sankar S, Webb DR, Bennett BL: CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 128:392–399, 2008. doi:10.1016/j.clim.2008.04.009

    Article  PubMed  CAS  Google Scholar 

  74. Wiernik PH, Lossos IS, Tuscano JM, et al.: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol, 2008, 26:4952–4957

    Google Scholar 

  75. Coiffier B,Haioun N, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capedeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 92:1927–1932, 1998.

    PubMed  CAS  Google Scholar 

  76. Wiernik PH, Vose JM, Moore TD, et al.: Results from a phase II study investigating the efficacy and safety of linalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. Proc Eur Hematol Assn, 2008

  77. Witzig TE, Wiernik PH, Moore T, et al.: Phase II multi-center study of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol, submitted, 2008

  78. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36–45, 2008.

    PubMed  CAS  Google Scholar 

  79. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984–5992, 2005. doi:10.1158/1078-0432.CCR-05-0577

    Article  PubMed  CAS  Google Scholar 

  80. Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544–1552, 2008. doi:10.1200/JCO.2007.14.5367

    Article  PubMed  CAS  Google Scholar 

  81. Friedberg JW: Treatment of follicular non-Hodgkin’s lymphoma: the old and the new. Semin Hematol 45S2:S2-S6, 2008.

    Article  CAS  Google Scholar 

  82. Leonard JP, Martin P, Barrientos J, Elstrom: Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 45S2:S11-S16, 2008.

    Article  CAS  Google Scholar 

  83. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bűhrer C, Henze G, Seeger K, Wellmann S: The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12:5526–5532, 2006. doi:10.1158/1078-0432.CCR-06-0719

    Article  PubMed  CAS  Google Scholar 

  84. Palladini G, Russo P, Lavatelli F, et al.: Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol, in press, 2008

  85. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA: The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465–470, 2007. doi:10.1182/blood-2006-07-032987

    Article  PubMed  CAS  Google Scholar 

  86. Hussein MA: Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95:924–930, 2006.

    PubMed  CAS  Google Scholar 

  87. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079–2080, 2006 doi:10.1056/NEJMc053530

    Article  PubMed  CAS  Google Scholar 

  88. Rajkumar SV, Blood E: Letter to the editor. N Engl J Med 354: 2080, 2006.

    CAS  Google Scholar 

  89. Gieseler F: Pathphysiological considerations in thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost 99:1001–1007, 2008.

    PubMed  CAS  Google Scholar 

  90. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A: Thromboembolic events with lenalidomide-base therapy for multiple myeloma. Cancer 112: 1522–1528, 2008. doi:10.1002/cncr.23336

    Article  PubMed  CAS  Google Scholar 

  91. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lillienfeld-Toal M, Lonial S, Morgan GJ, Oriowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–423, 2008. doi:10.1038/sj.leu.2405062

    Article  PubMed  CAS  Google Scholar 

  92. Johnson DC, Corthais S, Ramos C, et al.: Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood, in press, 2008

  93. Zonder JA, Barlogie B, Durie BGM, et al.: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006, 108:403. doi:10.1182/blood-2006-01-0154

  94. Niesvizky R, Martinez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M: Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48:2330–2337, 2007. doi:10.1080/10428190701647887

    Article  PubMed  CAS  Google Scholar 

  95. Drouet L: Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol (Paris) 56: 195–204, 2008. doi:10.1016/j.patbio.2008.02.013

    CAS  Google Scholar 

  96. Klein U, Kosely F, Hillengaß J, et al.: Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol, in press, 2008

  97. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P: Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296:2558–2560, 2006. doi:10.1001/jama.296.21.2558-c

    Article  PubMed  CAS  Google Scholar 

  98. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyll P, Trent D, Francis CW: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490–5505, 2007. doi:10.1200/JCO.2007.14.1283

    Article  PubMed  CAS  Google Scholar 

  99. Hirsh J: Riskof thrombosis with lenalidomide and its prevention with aspirin. Chest 131:275–277, 2007. doi:10.1378/chest.06-2360

    Article  PubMed  CAS  Google Scholar 

  100. Menon S, Habermann T, Witzig T: Lenalidomide-associated hypothyroidism. Leuk Lymphoma 48:2465–2467, 2007. doi:10.1080/10428190701704613

    Article  PubMed  Google Scholar 

  101. Darabi K, Kantammei S, Wiernik PH: Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 24: e59, 2006. doi:10.1200/JCO.2006.08.4053

    Article  PubMed  Google Scholar 

  102. McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA: The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. Int Immunopharmacol 6:1194–1203, 2006. doi:10.1016/j.intimp.2006.03.001

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center, Montefiore Medical Center—North Division, 600 East 233rd St., Bronx, NY, 10466, USA

    Peter H. Wiernik MD

  2. Departments of Medicine and Radiation Medicine, New York Medical College, New York, NY, USA

    Peter H. Wiernik MD

Authors
  1. Peter H. Wiernik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter H. Wiernik MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiernik, P.H. Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Curr. Treat. Options in Oncol. 10, 1–15 (2009). https://doi.org/10.1007/s11864-008-0077-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-008-0077-x

Keywords

Search

Navigation